These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 24463450)

  • 21. AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors.
    Rangel N; Rondon-Lagos M; Annaratone L; Aristizábal-Pachon AF; Cassoni P; Sapino A; Castellano I
    Cells; 2020 Apr; 9(4):. PubMed ID: 32344660
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes.
    Caan BJ; Sweeney C; Habel LA; Kwan ML; Kroenke CH; Weltzien EK; Quesenberry CP; Castillo A; Factor RE; Kushi LH; Bernard PS
    Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):725-34. PubMed ID: 24521998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status.
    Jiang HS; Kuang XY; Sun WL; Xu Y; Zheng YZ; Liu YR; Lang GT; Qiao F; Hu X; Shao ZM
    Oncotarget; 2016 Jul; 7(27):41285-41293. PubMed ID: 27285752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Normal Breast-Derived Epithelial Cells with Luminal and Intrinsic Subtype-Enriched Gene Expression Document Interindividual Differences in Their Differentiation Cascade.
    Kumar B; Prasad M; Bhat-Nakshatri P; Anjanappa M; Kalra M; Marino N; Storniolo AM; Rao X; Liu S; Wan J; Liu Y; Nakshatri H
    Cancer Res; 2018 Sep; 78(17):5107-5123. PubMed ID: 29997232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype.
    Dennison JB; Shahmoradgoli M; Liu W; Ju Z; Meric-Bernstam F; Perou CM; Sahin AA; Welm A; Oesterreich S; Sikora MJ; Brown RE; Mills GB
    Clin Cancer Res; 2016 Oct; 22(20):5068-5078. PubMed ID: 27172895
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas.
    Matos I; Dufloth R; Alvarenga M; Zeferino LC; Schmitt F
    Virchows Arch; 2005 Oct; 447(4):688-94. PubMed ID: 16012853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subtypes of Breast Cancer in Lao P.D.R.: A Study in a Limited-Resource Setting.
    Luangxay T; Virachith S; Hando K; Vilayvong S; Xaysomphet P; Arounlangsy P; Phongsavan K; Mieno MN; Honma N; Kitagawa M; Sawabe M
    Asian Pac J Cancer Prev; 2019 Feb; 20(2):589-594. PubMed ID: 30806064
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
    Sweeney C; Bernard PS; Factor RE; Kwan ML; Habel LA; Quesenberry CP; Shakespear K; Weltzien EK; Stijleman IJ; Davis CA; Ebbert MT; Castillo A; Kushi LH; Caan BJ
    Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):714-24. PubMed ID: 24521995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.
    Cheang MC; Voduc D; Bajdik C; Leung S; McKinney S; Chia SK; Perou CM; Nielsen TO
    Clin Cancer Res; 2008 Mar; 14(5):1368-76. PubMed ID: 18316557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
    Choi J; Jung WH; Koo JS
    Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
    Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
    BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses.
    Abd El-Rehim DM; Ball G; Pinder SE; Rakha E; Paish C; Robertson JF; Macmillan D; Blamey RW; Ellis IO
    Int J Cancer; 2005 Sep; 116(3):340-50. PubMed ID: 15818618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Poor-prognosis estrogen receptor-positive breast cancer identified by histopathologic subclassification.
    Webster LR; Lee SF; Ringland C; Morey AL; Hanby AM; Morgan G; Byth K; Mote PA; Provan PJ; Ellis IO; Green AR; Lamoury G; Ravdin P; Clarke CL; Ward RL; Balleine RL; Hawkins NJ
    Clin Cancer Res; 2008 Oct; 14(20):6625-33. PubMed ID: 18927304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mammographic density in relation to tumor biomarkers, molecular subtypes, and mode of detection in breast cancer.
    Sartor H; Zackrisson S; Elebro K; Hartman L; Borgquist S
    Cancer Causes Control; 2015 Jun; 26(6):931-9. PubMed ID: 25860114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of androgen receptor in breast cancer & its correlation with other steroid receptors & growth factors.
    Mishra AK; Agrawal U; Negi S; Bansal A; Mohil R; Chintamani C; Bhatnagar A; Bhatnagar D; Saxena S
    Indian J Med Res; 2012 Jun; 135(6):843-52. PubMed ID: 22825604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.